Systematic assessment of decision-analytic models for chronic myeloid leukemia.

While several well-designed models of CML treatment strategies exist, there remains a need for the assessment of the long-term efficacy and cost effectiveness of novel treatment options such as second-generation TKIs. Additionally, these models should be validated using independent data. Copyright Springer International Publishing Switzerland 2014